Biodesix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	49.09	38.21	54.51	45.56	24.55	20.43
Revenue Growth (YoY)	28.46%	-29.89%	19.64%	85.55%	20.16%	-
Cost of Revenue	13.01	14.15	30.52	22	6.07	4.41
Gross Profit	36.08	24.06	23.99	23.56	18.48	16.03
Selling, General & Admin	67.39	61.46	50.52	34.86	30.64	25.9
Research & Development	9.99	13.1	12.79	10.82	10.47	8.19
Other Operating Expenses	0.04	0.08	0	0	0	0
Operating Expenses	77.42	74.65	63.31	45.68	41.11	34.09
Operating Income	-41.34	-50.59	-39.32	-22.12	-22.63	-18.06
Interest Expense / Income	9.54	8.07	4.51	7.6	3.01	2.92
Other Expense / Income	1.27	6.79	-0.67	1.63	5.09	5.19
Pretax Income	-52.15	-65.45	-43.16	-31.35	-30.73	-26.17
Net Income	-52.15	-65.45	-43.16	-31.35	-30.73	-26.17
Shares Outstanding (Basic)	82	42	27	5	0	0
Shares Outstanding (Diluted)	82	42	27	5	0	0
Shares Change	95.03%	53.86%	465.63%	1899.17%	21.00%	-
EPS (Basic)	-0.64	-1.55	-1.58	-6.48	-126.97	-130.83
EPS (Diluted)	-0.64	-1.55	-1.58	-6.48	-126.97	-130.83
Free Cash Flow	-45.93	-48.51	-30.77	-23.54	-23.14	-18.29
Free Cash Flow Per Share	-0.56	-1.15	-1.12	-4.87	-95.63	-91.47
Gross Margin	73.50%	62.96%	44.01%	51.71%	75.26%	78.44%
Operating Margin	-84.22%	-132.39%	-72.14%	-48.55%	-92.16%	-88.40%
Profit Margin	-106.23%	-171.27%	-79.18%	-68.81%	-125.15%	-128.06%
Free Cash Flow Margin	-93.57%	-126.94%	-56.45%	-51.68%	-94.26%	-89.54%
EBITDA	-37.1	-51.53	-35.47	-20.84	-24.93	-21.51
EBITDA Margin	-75.59%	-134.86%	-65.08%	-45.75%	-101.52%	-105.28%
Depreciation & Amortization	5.51	5.84	3.18	2.9	2.79	1.74
EBIT	-42.61	-57.38	-38.65	-23.75	-27.72	-23.25
EBIT Margin	-86.81%	-150.15%	-70.91%	-52.12%	-112.90%	-113.79%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).